Aurobindo Pharma shares remain volatile after clarifying reports of a $5-5.5B Zentiva buyout were "premature." Analyst Deepak Pal said support near ₹995-1,020 offers a buy-on-dips zone, with potential upside to ₹1,250-1,300 if support holds. He cited strong US/EU launches, steady debt reduction, and exports, while cautioning on margin pressure, raw material costs, and USFDA risks.